BioPharmSignal logoBioPharmSignal

Biotech News

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

ALX Oncology (ALXO)ALX OncologyCompany update

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage

Related news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-30 12:00 EST

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

KYMRKymera2026-06-08 20:01 EST

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

GERNGeron2026-07-13 12:00 EST

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

CHRSCoherus BioSciences, Inc.2026-08-17 21:33 EST

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

KURAKura Oncology2026-08-07 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

ALX Oncology

CD47-Directed Immuno-Oncology ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells. Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other...

Recent company news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-30 20:40 EST

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALXOALX Oncology2026-06-30 12:00 EST

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALXOALX Oncology2026-06-01 12:00 EST

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALXOALX Oncology2026-05-08 12:00 EST

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
2.04 USD
Market cap
239.52M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States